We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-5.92%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$484M
AUM Growth
+$19.2M
Cap. Flow
+$80.6M
Cap. Flow %
16.65%
Top 10 Hldgs %
73.12%
Holding
59
New
4
Increased
1
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$76.1M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$6.17M
3
ATYR
aTyr Pharma
ATYR
+$3.83M
4
INZY
Inozyme Pharma
INZY
+$1.33M
5
CYPH
Cypherpunk Technologies Inc
CYPH
+$444K

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.65M
2
ALBO
Albireo Pharma Inc
ALBO
+$2.16M
3
ACLX
Arcellx
ACLX
+$1.45M
4
SWTX
SpringWorks Therapeutics
SWTX
+$578K
5
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$195K

Sector Composition

Rank Sector Weight
1 Healthcare 99.94%
2 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRZN icon
51
Surrozen
SRZN
$301M
$181K 0.04%
20,000
– –
NVAX icon
52
Novavax
NVAX
$1.31B
$147K 0.03%
21,244
– –
KRON
53
DELISTED
Kronos Bio
KRON
$114K 0.02%
78,131
– –
NGM
54
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$55.8K 0.01%
13,669
– –
NUVB.WS
55
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$16K ﹤0.01%
133,333
– –
SRZNW icon
56
Surrozen Inc Warrant
SRZNW
$8.86K
$10K ﹤0.01%
99,999
– –
NVAX icon
57
CALL
Novavax
NVAX
$1.31B
– –
-23,400
Closed -$241K
SWTX
58
DELISTED
SpringWorks Therapeutics
SWTX
– –
-22,204
Closed -$578K
ALBO
59
DELISTED
Albireo Pharma Inc
ALBO
– –
-100,000
Closed -$2.16M
1 2
3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q1 2023 Portfolio in Review

As of Q1 2023, Samsara BioCapital held 59 positions worth $484M, up 4.1% from $465M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Samsara BioCapital deployed $80.6M of net new capital in Q1 2023, opening 4 new positions and adding to 1 existing holding. Its largest new stake was Mineralys Therapeutics: 4,519,361 shares worth $70.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $2.65M trimmed.

  • Samsara BioCapital's largest Q1 2023 buy was Mineralys Therapeutics: 4,519,361 shares worth $70.8M.
  • Samsara BioCapital added most to Avadel Pharmaceuticals in Q1 2023, an estimated $6.17M increase.
  • Samsara BioCapital's biggest Q1 2023 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $2.65M.
  • Samsara BioCapital fully exited Albireo Pharma Inc in Q1 2023, selling an estimated $2.16M.
  • Samsara BioCapital's ten largest holdings make up 73% of its $484M portfolio in Q1 2023.
  • Samsara BioCapital opened 4 new positions and closed 3 in Q1 2023.
  • Samsara BioCapital's portfolio value rose 4.1% quarter-over-quarter to $484M.

Based on Samsara BioCapital's 13F filing for Q1 2023, filed 15 May 2023.